Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update

References

• Koyama AK, Cheng YJ, Brinks R, et al. Trends in lifetime risk and years of potential life lost from diabetes in the United States, 1997–2018. PLOS ONE. 2022;17(5):e0268805. doi: 10.1371/journal.pone.0268805
   PubMed Web of Science ®Google Scholar
• Zhang R, Mamza JB, Morris T, et al. Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med. 2022;20(1):63. doi: 10.1186/s12916-022-02234-2
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;12(11):1267–1271. doi: 10.1080/17425255.2016.1234608
   PubMed Web of Science ®Google Scholar
• Marx N, Federici M, Schutt K, et al. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: 10.1093/eurheartj/ehad192
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Bannuru RR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care. 2024;47(Supplement_1):S158–S178. doi: 10.2337/dc24-S009
   PubMedGoogle Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034
   PubMed Web of Science ®Google Scholar
• Cho YK, La Lee Y, Jung CH. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. J Lipid Atheroscler. 2023;12(3):213–222. doi: 10.12997/jla.2023.12.3.213
   PubMedGoogle Scholar
• Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–598. doi: 10.1038/s41591-022-01707-4
   PubMed Web of Science ®Google Scholar
• A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT). [cited 2024 Mar 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT04255433
   Google Scholar
• DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat rev Nephrol. 2017;13(1):11–26. doi: 10.1038/nrneph.2016.170
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep. 2019;21(8):70. doi: 10.1007/s11886-019-1165-1
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39(5):717–725. doi: 10.2337/dc16-0041
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031. doi: 10.1210/jc.2011-2260
   PubMed Web of Science ®Google Scholar
• Pandey AK, Bhatt DL, Pandey A, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44(37):3640–3651. doi: 10.1093/eurheartj/ehad389
   PubMed Web of Science ®Google Scholar
• Zhang Y, He Y, Liu S, et al. SGLT2 inhibitors in aging-related cardiovascular disease: a review of potential mechanisms. Am J Cardiovasc Drugs. 2023;23(6):641–662. doi: 10.1007/s40256-023-00602-8
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi: 10.1056/NEJMra0800885
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319–334. doi: 10.1038/s41581-021-00393-8
   PubMed Web of Science ®Google Scholar
• Bechmann LE, Emanuelsson F, Nordestgaard BG, et al. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2023;117236. doi: 10.1016/j.atherosclerosis.2023.117236
   PubMedGoogle Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639. doi: 10.1093/eurheartj/ehad195
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–158. doi: 10.1001/jamacardio.2020.4511
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Bannuru RR, et al. 11. ChroniC kidney disease and risk management: standards of care in diabetes—2023. Diabetes Care. 2024;47(Supplement_1):S219–S230. doi: 10.2337/dc24-S011
   PubMedGoogle Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59. doi: 10.1007/s40265-014-0337-y
   PubMed Web of Science ®Google Scholar
• Zhao Q, Tan Y, Wu Q, et al. The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study. Expert Opin Drug Saf. 2024;23(1):57–65. doi: 10.1080/14740338.2023.2275704
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Dalsgaard NB, Vilsbøll T, Knop FK. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes Obesity Metab. 2018;20(3):508–519. doi: 10.1111/dom.13128
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–870. doi: 10.1161/CIRCULATIONAHA.117.028136
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Kawabe A, Matsumura M, et al. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care. 2016;39(2):e22–3. doi: 10.2337/dc15-1437
   PubMed Web of Science ®Google Scholar
• Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280–1290. doi: 10.1210/en.2013-1934
   PubMed Web of Science ®Google Scholar
• Hoffman S, Alvares D, Adeli K. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Mol Metabol. 2022;65:101590. doi: 10.1016/j.molmet.2022.101590
   PubMed Web of Science ®Google Scholar
• Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–662. doi: 10.1016/S2213-8587(21)00203-5
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868
   PubMed Web of Science ®Google Scholar
• Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obesity Metab. 2017;19(3):336–347. doi: 10.1111/dom.12824
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528–542. doi: 10.1002/dmrr.1202
   PubMed Web of Science ®Google Scholar